[Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin].
The therapeutic effect of combined chemoembolization with lipiodol, epirubicin and cisplatin in 22 patients with nonresectable tumours, predominantly in livers with cirrhotic transformation, was analysed. Lipiodol was demonstrated in tumour tissue on average three months, maximally six months, after injection. Repeat embolization was done, if possible, after storage had subsided. There were only minor side effects. Quality of life suffered only from the, though delayed, continuing cancer growth. Survival rate was 73% after six months, 54% after one year.
Bokemeyer
B
B
Zentrum Innere Medizin, Medizinischen Hochschule Hannover.
Grote
R
R
Schmoll
E
E
Freise
J
J
Schmoll
H J
HJ
Galanski
M
M
Schüler
A
A
Schmidt
F W
FW
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage*; D004338:Drug Combinations; D004621:Embolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D007269:Injections, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors
D004338:Drug Combinations; D015251:Epirubicin; D007459:Iodized Oil; D002945:Cisplatin
Chemoembolisation hepatozellulärer Karzinome mit Lipiodol, Epirubicin und Cisplatin.